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Human herpesvirus 8 (HHV8) infection leads to potent activation of nuclear factor kappa
B (NFκB) in primary and transformed cells. We used recombinant HHV8 (rKSHV.219)
expressing green fluorescent protein under the constitutive cellular promoter elongation
factor 2α and red fluorescent protein under an early HHV8 lytic gene promoter T1.1 to
monitor replication during infection of human foreskin fibroblasts (HF), noting changes in
NFκB activity. In primary HF, NFκB levels do not affect the ability of HHV8 to establish
infection or maintain latency. Furthermore, there was no effect on the percent of cells
undergoing reactivation from latency, and there were similar numbers of released and
cell-associated HHV8 viral particles following reactivation in the presence of inhibitors.
Reactivation of HHV8 in latently infected HF in the presence of NFκB inhibitors resulted in
production of viral particles that did not efficiently establish infection, due to deficiencies in
binding and/or entry into normally permissive cells. Exogenous expression of glycoprotein
M, an envelope protein involved in viral binding and entry, was able to partially overcome
the deficiency induced by NFκB inhibitors. Our data indicate that in primary cells, NFκB
is not required for infection, establishment of latency, or entry into the lytic cycle, but is
required for the expression of virion associated genes involved in the initial steps of virion
infectivity.These studies suggest that strategies to inhibit NFκB may prevent HHV8 spread
and should be considered as a potential therapeutic target for preventing HHV8 associated
diseases.
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INTRODUCTION
Human herpesvirus 8 (HHV8), also called Kaposi’s sarcoma asso-
ciated herpesvirus (KSHV), is a deoxyribonucleic acid (DNA)
tumor virus that is epidemiologically and molecularly linked to
multiple proliferative disorders including: endothelial cell based
tumor Kaposi’s Sarcoma (Soulier et al., 1995); B cell tumors;
pleural effusion lymphoma (PEL), also known as body cav-
ity based lymphoma (BCBL); and the plasmablastic variant of
Multicentric Castleman’s Disease (Inglesby et al., 1999). Per-
sistent HHV8 infection is characterized by both latency and
lytic replication, and diseases associated with HHV8 infection
appear to be the result of both long-term latent infection and
viral reactivation. Latent infection is associated with the absence
of virus production and the expression of a limited number
of viral genes, many of which provide a survival advantage
(Dittmer et al., 1998; Ensoli et al., 2001; Fakhari and Dittmer,
2002). Lytic replication is characterized by the timely expres-
sion of immediate early, early, and late genes resulting in
the release of mature virions. Lytic replication is thought to
aid in tumorigenesis by increasing the pool of infected cells
and lytic genes may also have paracrine properties that might
provide neighboring cells with proliferation and/or survival
advantage (Dupin et al., 1999; Ensoli et al., 2001; Boulanger et al.,
2004).
Nuclear factor kappa B (NFκB) is an important transcription
factor involved in the lifecycle of many herpesviruses, includ-
ing HHV8 (Keller et al., 2000; Hummel et al., 2001; Hummel
and Abecassis, 2002; Guasparri et al., 2004; Stewart et al., 2004;
Sadagopan et al., 2007; Grossmann and Ganem, 2008). NFκB
is involved in the cellular processes like inflammation, cell
proliferation, protection from apoptosis, and viral gene expres-
sion. Deregulation of NFκB has been linked to lymphomas
caused by Epstein-Barr Virus (EBV) infection as well as viral
reactivation in Cytomegalovirus (CMV) infected cells (Hum-
mel et al., 2001; Hummel and Abecassis, 2002; Stewart et al.,
2004). HHV8 has multiple NFκB binding sites in its genome
regulating both latent and lytic genes, and NFκB activity is up
regulated during infection (Keller et al., 2000; Lagunoff et al.,
2001; Guasparri et al., 2004; Sadagopan et al., 2007; Gross-
mann and Ganem, 2008). NFκB has been implicated as a
survival factor for HHV8 latently infected cells and thought to
be involved in HHV8 lytic replication (Keller et al., 2000; Guas-
parri et al., 2004; Sgarbanti et al., 2004; Grossmann and Ganem,
2008).
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A number of cell culture systems in which to study HHV8
replication and the role of NFκB have been used. BCBL-1 cells,
a line created from a PEL, have been used to study HHV8 exten-
sively; however, BCBL-1 cells predominantly maintain HHV8 in
the latent state, with a low percentage of lytically replicating cells
at all times. As a population, the cells exhibit high levels of con-
stitutive NFκB activity. Reduction of NFκB levels in PEL cells
by specific inhibitors results in apoptosis and increased sensitiv-
ity to apoptotic stimuli (Guasparri et al., 2004). However, some
studies have suggested that increased NFκB levels are required
for lytic gene expression (Sgarbanti et al., 2004; Grossmann and
Ganem, 2008). Additional work has shown NFκB has inhibitory
effects on lytic viral gene promoters, suggesting that NFκB sup-
presses lytic viral gene expression (Brown et al., 2003). Grossmann
and Ganem (2008) confirmed the dependence of PEL cells on
NFκB for maintenance of latency, and found that lytic gene
expression was enhanced during blockade of NFκB. Consistent
with these results, blockade of NFκB in PEL cells correlated with
the increased expression of the lytic genes ORF K8.1 and ORF
59 (Brown et al., 2003). Additionally, Grossmann and Ganem
(2008) demonstrated that this does not seem to be universal, as
human foreskin fibroblasts (HF) and microvascular endothelial
cells (MVEC) do not exhibit this phenotype after NFκB inhi-
bition, for the first time demonstrating that NFκB dependence
may be cell type specific. Furthermore, since B-cell transfor-
mation is often dependent upon deregulation of NFκB, NFκB
induced events leading to viral reactivation in transformed B cells
may not adequately reflect cellular events that occur during viral
reactivation in non-transformed primary cells. Sadagopan et al.
(2007) found that NFκB levels increased within minutes of infec-
tion with HHV8 and remained elevated, directly affecting latent
and lytic gene expression levels. They did not however, evaluate
the role of NFκB during viral reactivation and virion produc-
tion. Given these conflicting results about the role of NFκB in
transformed cells it is important to examine the role of NFκB
in viral reactivation and virus production during HHV8 infec-
tion of primary human cells that survive independent of NFκB
signaling.
To assess the role of NFκB in HHV8 infection, particularly
during viral reactivation, we utilized an HHV8 infection model
previously developed in primary HF as well as an additional model
using MVEC (Lagunoff et al., 2002; Vieira and O’Hearn, 2004).
We found that NFκB levels increase shortly after infection, remain
elevated during latency, and increase dramatically during reacti-
vation. Interestingly, while in the presence or absence of NFκB
inhibitors an equivalent percentage of cells underwent viral reac-
tivation and similar numbers of virus particles were produced;
however, there was a stark decrease in the production of infectious
virions. This effect could be partially rescued by expression of the
KSHV lytic gene gM.
MATERIALS AND METHODS
CELL CULTURE AND NFκB INHIBITORS
Human foreskin fibroblasts (HF) and 293 cells were grown in
Dulbeco’s Modified Eagles Media supplemented with 10% heat
inactivated FBS and 1% pen/strep. MVEC were grown in endothe-
lial basal medium-2 with bullet kit additives (Lonza). Stable
rKSHV.219 infection was established by infection of HF cells with
a multiplicity of infection (MOI) of 10. rKSHV.219 contains a
puromycin resistance cassette and after 72 h the infected cells
were selected with puromycin. HF cells infected with rKSHV.219
were maintained under the same selection (Lagunoff et al., 2002;
Vieira and O’Hearn, 2004). In order to inhibit NFκB activity
two methods were chosen. First, where indicated, cells were
treated with the irreversible small molecule inhibitor of NFκB,
Bay11-7082, at 5 μM and 2.5 μM to HF and MVEC cells, respec-
tively. Alternatively, we also utilized a dominant negative form
of the inhibitor of NFκB(IκBα) containing two point mutations
(32/36S/A) expressed via a DNA vector (pCMV-IκBα-DN, cour-
tesy of D. Ballard, Vanderbilt University). One μg of a Cyan
fluorescent protein expression vector was used as a transfection
efficiency control. Bay11-7082 treatments were as follows: cells
were treated with 5 or 2.5 uM Bay11-7082 or a DMSO control for
24 h prior to the start of the experiment and for the duration of
the experiment; for the “Post” samples, cells were treated with 5 or
2.5 uM Bay11-7082 at time of induction of lytic replication and
for the duration of the experiment.
VIRAL INFECTION, INDUCTION AND QUANTITATION
Recombinant HHV8 construction and infection of HF, viral repli-
cation induction and viral titer quantitation were performed as
previously described (Vieira and O’Hearn, 2004). Infection of
MVEC was performed in 12 well plates at an MOI of 10 (Lagunoff
et al., 2002). Two h post infection, viral reactivation was induced
using a recombinant adenovirus expressing the gene for the viral
transactivator ORF50 [a gift from D. Ganem, UC, San Fran-
cisco (Glaunsinger)] in the presence of sodium butyrate and
after 24 h the cells were washed with PBS and media replaced.
Viral titer was determined with cell debris free supernatant incu-
bated with 293 cells as previously described (Vieira and O’Hearn,
2004; Chen and Lagunoff, 2007). In all groups, mock inductions
with sodium butyrate were performed as negative controls. To
measure cell-associated virus, cells were harvested and the cell
fraction was sonicated on ice for 10 s at 3-min intervals (repeated
three times). Cell debris was pelleted and supernatant used to
infect 293 cells. Original supernatant was used to quantitate viral
titer.
NFκB LUCIFERASE REPORTER ASSAY
Human foreskin fibroblasts were electroporated with the follow-
ing luciferase reporter vectors then plated at 2 x 105 cells/well
in 12-well plates: pF-Luc (10 μg), a control vector containing
two mutated NFκB consensus sites unable to bind NFκB; and
pBXII-Luc (10 μg), which contains two tandem repeats of the
NFκB consensus sites to reflect NFκB activity. A β-galactosidase
(βgal) expression vector driven by a CMV promoter (1 μg) was
used to measure transfection efficiency. To control for NFκB spe-
cific reporter activity, we utilized a dominant negative version
of the NFκB inhibitor IκBα-DN (5 μg), which contains ser-
ine to alanine substitutions at amino acid positions 32 and 36,
preventing phosphorylation and subsequent release of NFκB for
translocation into the nucleus. Cells were harvested according to
Promega Luciferase Assay Reagent protocol (E4030) 24 h post
transfection and assayed for luminescence (TD Luminometer).
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Each transfection was performed in triplicate and read three
times.
IMMUNOHISTOCHEMISTRY AND FLOW CYTOMETRY
Cells were harvested at 72 h post induction of viral replication.
All staining was performed on ice in PBS, 1% BSA, and 0.1%
sodium azide. Cells were washed twice with PBS then stained
with the K8.1 primary antibody at 1:100 in 5% FBS for 1 h.
Cells were washed three times with PBS and stained with the
secondary antibody anti-mouse Alexa 680 (Molecular Probes)
at 1:1000 for 30 min then washed. Microscopy was performed
with the Nikon Eclipse TE300 inverted fluorescent microscope
equipped with filter sets TE300 FITC, TE300 Texas Red HYQ,
and TE300 633. Images were acquired with a Photometrics Cool-
Snap cf digital camera and MetaVue imaging software at 20X
amplification. Cells were analyzed by flow cytometry on an LSRII
(Beckman-Coulter).
ELECTROMOBILITY SHIFT ASSAYS
A quantity of 5 × 106 HF and HF219 cells were washed in cold PBS
before use of the NFκB specific Promega Gel Shift Assay System
(E3050, E3300) utilizing the Promega NFκB specific probe (5′-
AGT TGA GGG GAC TTT CCCAGG C-3′) as directed. For super-
shift experiments, nuclear extracts were incubated with human
p65 (SantaCruzBiotechnology) for 30min on ice prior to addition
of radiolabeled oligonucleotide and gel electrophoresis. Samples
were run on 7% acrylamide gels and assessed by exposure to blue
x-ray film (Phenix Research Products).
QUANTITATION OF VIRIONS
Supernatant harvested from uninduced and induced cells were
filtered through 0.45 μm filters then centrifuged in rotor SS35
at 23 K RPM for 2 h at 4◦ C. The pellet was DNase treated
for 1 h. As an internal control for non-encapsulated viral DNA,
naked HSV gB (herpes simplexvirus glycoprotein B) DNA was
added in known quantity to samples prior to DNAse treatment
and subsequently analyzed by qPCR for HHV8 genes ORF73
and HSV gB (Molecular Virology Laboratories). Viral DNA
copy number in 293 cells was measured by inducing HF219
cells, harvesting the supernatant and infecting 293 cells as previ-
ously described above. Four h post-infection cells were washed
with PBS then DNAse treated as above. DNA from the final
wash mixed with 293 cells was used for quantitative HHV8
PCR (ORF73), normalizing to beta globin (Molecular Virology
Laboratories, UW).
VIRAL GENE ARRAYS
Content of the viral arrays has been previously described (Chen
and Lagunoff, 2007). The nitrocellulose membrane arrays con-
tained 89 HHV8 genes and GAPDH and actin as cellular RNA
controls. Messenger RNA was extracted using Qiagen RNeasy
and Oligotex kits from control and experimental groups. cDNA
was made using superscript II (Invitrogen) with random primers
and P32 labeled dCTP. Labeled cDNA was then used to probe
viral arrays overnight. The blots were then exposed to a phos-
phoimager screen and hybridization quantitated using a Typhoon
scanner.
REAL TIME PCR
AppliedBiosystemsprogramPrimerExpress 1.5wasused todesign
primers based on the sequences for all seven genes identified by
viral arrays as well as T1.1 and K8.1 control genes. Supplementary
Table 1 lists the primers used for this study. RNA was extracted
using the Qiagen RNeasy kit. Briefly, 20 ug of RNA was treated
with amplification grade DNase (Invitrogen) for 30 min followed
by randomprimer reverse transcriptase PCR (100uL reaction) and
2 uL was used for rRNA and 5 uL for gene specific amplification.
Primers were first tested on uninfected HF and uninduced HF219
cells to ensure specificity. Ribosomal RNA was quantitated using
a ribosomal RNA reagents kit with VIC probes and SYBER Green
mastermix (Applied Biosciences). Reactionswere performed in an
ABI Prism 7700 sequence detector. PCR results were normalized
to rRNA levels.
gM COMPLEMENTATION
Deoxyribonucleic acid encoding glycoprotein M was amplified
using the primers 5′-TGAAAACAGCAGCATTTCCAA-3′ and 5′-
TACTGACTCGGTGAAACC-3′. The PCR product was blunt
ligated into the pIRES2 vector (Lonza) and constructs were
sequenced to ensure correct coding sequence and orientation. Five
micrograms of vector alone or gM construct were electroporated
into cells and plated at 2 x 105 cells per well and 24 h later cells
were harvested and RNA extracted as described above. gM com-
plementation was evaluated by inducing lytic replication and virus
titer 24 h after transfecting cells.
RESULTS
INFECTION WITH rKSHV.219 INDUCES NFκB SIGNALING
We assessed the impact of HHV8 infection on active NFκB lev-
els in primary HF. Cells were infected with rKSHV.219 at a MOI
of 10 green fluorescent protein (GFP) forming units; this MOI
is known to result in adequate levels of infection (30−50%) with
little cell toxicity, a lower MOI results in inefficient infection of HF
cells. GFP forming units were calculated by rKSHV.219 virus titer
on 293 cells as previously described as a measure of MOI (Vieira
and O’Hearn, 2004). Cell lysates were harvested 72 h post- infec-
tion and NFκB activity, assessed as binding to promoter DNA,
was assayed by electromobility shift assay. NFκB consensus sites
(5′-GGGRNNYYCC-3′) are present at several locations within the
HHV8genome, particularly upstreamof lytic genes.We found that
upon infection with rKSHV.219, HF cells had a relative increase
in nuclear translocation of NFκB as demonstrated by electromo-
bility shift assay (EMSA; Figure 1A). To determine specificity of
the assay, antibody directed against the p65 subunit of NFκB was
added. In order to enumerate NFκB activity we transfected HF
cells accordingly with plasmids driven by either mutated, non-
consensus NFκB sites (Dupin et al., 1999) or two tandem NFκB
sites (Tandem) driving luciferase. A β-galactosidase transfection
control was used to normalize for transfection efficiency. A subset
of cells were cotransfected with a dominant negative IκBα (IκBα-
DN), a mutated form of the NFκB inhibitor that contains two
point mutations (S32A and S36A), which remove phosphoryla-
tion sites required for proteasome degradation, thereby resulting
in constitutive NFκB inhibition. Expression of IκBα-DN led to
decreased NFκB signaling by sequestering NFκB in the cytoplasm.
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FIGURE 1 | rKSHV.219 leads to constitutive NFκB activation in HF. (A) HF
cells were either mock infected or infected with rKSHV.219 at a MOI of 10. At
72 h post-infection 2 x 105 cells were harvested and 2 uL of nuclear extracts
were characterized by EMSA using an NFκB–specific radiolabeled probe.
Lane 1, H2O; 2, Nuclear extract (NE); 3, cold NFκB 50-fold molar excess
probe (Comp.); 4, Non-competitive probe (Non-comp.); and 5, super shift with
an anti-p65 antibody (p65 sup. Shift; *). Arrows denote protein subunits p50
and p65. This is a representative of three separate experiments. (B) HF cells
were transfected with NFκB-driven luciferase plasmids: pF-Luc,
mutated/nonconsensus NFκB binding sites (Dupin et al., 1999); and
pBXII-Luc, two tandem consensus NFκB binding sites (Tandem).When
indicated, cells were also cotransfected with IκBα-DN (Fenner et al., 1998).
Cells were infected with rKSHV.219 and luciferase values were enumerated.
All values reflect increases over uninfected controls, which were set to 1.
Error bars represent standard deviations of the mean, calculated from one
representative experiment performed in triplicate. *p < 0.0001 infected vs.
uninfected fibroblasts, and **p < .0001 infected vs. uninfected expressing
IκBα-DN.
Cells infected with rKSHV.219 had nearly a 28-fold increase in
NFκB driven luciferase activity as compared to uninfected con-
trols (Figure 1B). This increase in luciferase gene expression was
partially inhibited by IκBα-DN.
INHIBITION OF NFκB DOES NOT AFFECT LYTIC GENE EXPRESSION AND
VIRAL REACTIVATION
To further investigate NFκB activity during the viral life cycle we
measured NFκB-dependent gene expression during viral reactiva-
tion. We either mock infected or infected HF cells with rKSHV.219
at an MOI of 10. rKSHV.219 contains a puromycin resistance
cassette and infected cells were selected for puromycin resistance
until cells were confluent, approximately 7 days later (Vieira and
O’Hearn, 2004). Infected and mock-infected HF cells were elec-
troporated with luciferase constructs as described above. Both cell
populations were transfected with IκBα-DN-containing or empty
vectors and were then induced to undergo productive lytic repli-
cation. It has previously been shown that ectopic expression of
HHV8 ORF50 by a recombinant baculovirus (BacK50) in HF cells
induces the virus from a latent to a lytic, replicating state, and that
sodium butyrate significantly enhances ORF50-dependent virus
production (Vieira and O’Hearn, 2004). Since transfection effi-
ciency in primary HF cells is approximately 30%, we also utilized
a non-reversible small molecule inhibitor of NFκB, Bay11-7082,
and compared its effect on NFκB activity with that of IκBα-DN.
We did evaluate the cell toxicity of Bay11-7082 by performing a
dose response assay and found optimal inhibition of NFκB and
minimal cell toxicity at 5 μM (data not shown). Where indicated,
cells were treated with 5 μM Bay11-7082 or DMSO either 24 h
prior to induction of lytic replication (Total) or at the time of
induction (Post). We induced lytic replication of rKSHV.219 in
HF cells (and mock infected cells) by infecting with BacK50 at an
MOI of 40 as previously described (Vieira and O’Hearn, 2004),
harvested cell lysates 4, 12, 24, 48, and 72 h post induction of
lytic replication, and measured luciferase activity. After normaliz-
ing for transfection efficiency, we observed NFκB-driven luciferase
expression at 4 h post induction, and by 72 h had increased to 25-
fold higher than that of uninfected cells (Figure 2A). Treatment
of cells with Bay11-7082 or transfection with IκBα-DN signifi-
cantly inhibited NFκB driven luciferase activity, decreasing it by
5-fold.
We next sought to determine if inhibition of NFκB by Bay11-
7082 or IκBα-DN resulted in spontaneous reactivation or inhibi-
tion of viral reactivation. HF cells infected with rKSHV.219 were
either treated with Bay11-7082 or electroporated with IκBα-DN,
and 24 h later induced to undergo lytic replication. After 48 h,
cells were harvested and analyzed for GFP and RFP expression by
microscopy, aswell asRFPbyflowcytometry. All cells infectedwith
rKSHV.219 fluoresced green and uninduced cells did not undergo
reactivation, as evidenced by lack of RFP expression (Figure 2B).
Amongst the groups induced to undergo lytic replication, there
was no difference in the number of RFP positive cells between the
3 treatment groups, suggesting that inhibition of NFκB does not
alter the ability of rKSHV.219 to enter the lytic cycle (Figure 2C).
To determine if late gene expression, in addition to early gene T1.1
expression,was affected byNFκB inhibition,we assayed for expres-
sion of the HHV8 late gene ORF K8.1 (Figure 2C). There was no
significant difference in K8.1 protein expression in control, Bay11-
7082 treated or IκBα-DN transfected cells. Interestingly, neither
the T1.1 nor ORFK8.1 promoters contain an NFκB consensus site
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FIGURE 2 | NFκB inhibition does not affect viral reactivation. (A–C)
HF cells either mock infected or infected with rKSHV.219, transfected
with pBXII-Luc and then induced to undergo lytic replication, except for
the Uninduced sample. When indicated, cells were either mock treated
(No inhibitor), cotransfected with IκBα-DN or treated with Bay11-7082
prior to induction (Total) or at time of induction (Post). (A) Cell lysates
were harvested; luciferase values reflect NFκB activation as the
fold-increase of infected/uninfected samples (set to 1); mean ± SD from
triplicate transfections in one experiment, representative of three
independent experiments. Student’s t -test was used for statistical
analysis. (B) Cells were harvested and GFP expression (indicating
infection) and RFP expression (RFP driven by ORF50 promoter,
indicating viral reactivation) was visualized via fluorescence microscopy
at 20X magnification. (C) Histograms showing the percentage of RFP
positive cells and K8.1 protein expression as measured by flow
cytometry; histogram values represent mean fluorescence intensity (MFI)
of 5 x 106 cells. The cells shown on the histogram are gated for GFP
positive cells, which represents >99% of cells analyzed as all cells are
maintained under puromycin selection. Data are representative of three
independent experiments.
(Russo et al., 1996). Treatment of rKSHV.219 infected HF cells
with NFκB inhibitors did not lead to spontaneous reactivation
(Figure 2B, Vieira and O’Hearn, 2004).
NFκB IS REQUIRED TO PRODUCE INFECTIOUS VIRIONS
Because NFκB inhibition in PEL cells results in apoptosis and
decreased viral reactivation, we assessed whether our three
inhibitory methods would also reduce reactivation and virion
production in HF cells. rKSHV.219-infected HF cells were either
electroporated with IκBα-DN, treated with no inhibitor or treated
with Bay11-7082 (Total, Post). We measured GFP forming units
from supernatant collected at 24, 48, and 72 h post induction on
293 cells. Viral titer from induced HF cells increased to over 15,000
GFUby 72 h post-infection frombasal levels (Figure 3A).With the
addition of NFκB inhibitor Bay11-7082, both Total and Post, these
titers dropped over three fold. Similarly low titers were seen from
cells expressing IκBα-DN.These data demonstrate thatNFκB inhi-
bition can result in reduced viral titers from rKSHV.219-infected
cells. To determine if these findings applied to other primary cells
infected with HHV8, we performed the assay in MVEC cells and
found similar results to HF cells (Figure 3B). Higher GFU were
observed in MVEC, as these cells are a more permissive cell line
to HHV8 infection and do have a low percentage of cells that
undergo spontaneous lytic replication unlike HF as previously
shown (Lagunoff et al., 2002).
Since inhibition of NFκB did not affect viral lytic reactiva-
tion but did result in decreased viral titers, we evaluated whether
NFκB inhibition resulted in sequestrationof virus in the cytoplasm
of induced cells. We analyzed titers of cell-associated virus from
induced rKSHV.219-infected HF cells following no treatment,
treatment with Bay11-7082, or transfection with IκBα-DN. Cell-
associated virus from Bay11-7082 treated cells and cells expressing
IκBα-DN showed a similar drop in viral titer to virus collected
from the supernatant, as compared to no treatment positive con-
trols (Figure 3C). This suggests that the decrease in viral titer
seen in cells treated with NFκB inhibitors was not secondary to
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FIGURE 3 | Cell induction in the presence of NFκB inhibition
decreases viral titers. (A,B) rKSHV.219-infected HF (A) or MVEC
(B) cells were either mock induced (Uninduced) or induced to
undergo lytic replication with BacK50 (A) or Ad50 (B) and then
treated with Bay11-7082 prior to induction (Total), at the time of
induction (Post), or transfected with IκBα-DN prior to induction.
Supernatants were harvested at 24, 48, and 72 h post induction
(A) and GFP forming units on 293 cells were measured. Using
paired T test there was statistical significance between control
induction and all treatment groups at both 48 h *p < 0.032,
0.0371, and 0.033; and 72 h **p < 0.03, 0.033, 0.037. (B) MVEC
titers at 72 h post induction assessed on 293 cells. P values
calculated as compared with control inductions done with Ad50.
*p < 0.0071, **p < 0.0035, ***p < 0.007. (C) Viral titers,
measured by GFP forming units, from HF cell lysates described in
(A). Using paired T test there was statistical significance between
control induction and all treatment groups at 48 h *p < 0.045,
0.022, 0.0088 and < 0.03; and 72 h **p < 0.007, 0.002, 0.001.
Samples were assayed in triplicate and are representative of three
experiments.
sequestration of virus within the productively replicating cell but
by potentially some other process.
To further evaluate possible mechanisms for the observed
reduction in viral titer caused by NFκB inhibition, we set out to
measure HHV8 DNA copies in the cell supernatant. rKSHV.219-
infected HF cells treated with vehicle control, Bay11-7082, or
electroporated with IκBα-DN were induced and cell supernatant
was harvested for DNA extraction. Prior to DNA extraction a
known quantity of HSV gB was added to each sample, which
was then treated with DNase; this step was to ensure all extra-
cellular (non-virion associated) DNA was degraded. Quantitative
real-time PCR was performed for HHV8 ORF73 and HSV gB.
All samples were negative for gB DNA, suggesting adequate
degradation of un-encapsulated DNA. We observed no difference
between HHV8 virus particle-associated DNA from supernatants
of induced rKSHV.219-infected HF cells and those treated with
NFκB inhibitors, indicating that similar numbers of DNA con-
taining virus particles were released from cells (Figure 4A). Thus
far we have found that viral reactivation occurs in the pres-
ence of NFκB inhibitors and similar numbers of viral particles
are produced, however, there is a significant drop in viral
titers from both cell-associated and supernatant of cells induced
to undergo productive replication in the presence of NFκB
inhibitors.
In order to distinguish between defects in HHV8 viral par-
ticle binding and entry versus defects in subsequent steps in
viral infection, we infected permissive 293 cells with supernatants
from induced rKSHV.219-infected HF cells in the presence of
Bay11-7082 or electroporated with IκBα-DN. We harvested viri-
ons from supernatant, as described above, and then infected 293
cells. Four hours after infection the cells were washed thrice
with cold PBS and the last wash and cell pellet were sub-
jected to quantitative PCR to enumerate HHV8 DNA found
in the target 293 cells. The last wash in all groups did not
amplify viral DNA. The number of viral DNA copies found
per cell at four hours post-infection was dramatically lower in
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FIGURE 4 | Decreased viral entry by HHV8 virions in the presence of
NFκB inhibitors. rKSHV.219-infected HF cells were either mock induced
(Uninduced) or induced to undergo lytic replication and then treated
with Bay11-7082 prior to induction (Total), at the time of induction
(Post), or transfected with IκBα-DN prior to induction. Supernatants were
harvested 72 h post induction. (A) HHV8 DNA copy number was
quantitated for cell supernatants by real time RT-PCR at 72 h post
induction. There is no statistically significant difference between
samples. Assay was done in triplicate and a representative of three
experiments is shown. (B) DNA was extracted from supernatants from
rKSHV.219 infected HF cells induced to undergo lytic replication, except
for the Uninduced sample. When indicated, cells were either mock
treated (No inhibitor, DMSO only), cotransfected with IκBα-DN or treated
with Bay11-7082 prior to induction (Total) or at time of induction (Post).
Viral DNA was quantitated by real time PCR (). Cell number was
calculated by β-globin copy number. Supernatants were used in a viral
titer assay on 293 cells to enumerate GFP forming units ().Samples
were assayed in triplicate and are representative of three experiments.
For all experiments, 1 x 105 cells were used. P values as follow for
GFPF/mL as compared to induction only: *p < 0.043, **p < 0.0541,
and ***p < 0.0349. For viral DNA copies/cell as compared to
induction only: *p < 0.0489, **p < 0.0718, and ***p < 0.0340.
cells treated with Bay11-7082 or IκBα-DN, suggesting a block
in virus binding or entry into target cells when virus is pro-
duced in the presence of an NFκB inhibitor (Figure 4B). Viral
DNA copies per cell correlated with viral titer, quantitated by
a viral titer assay performed with aliquots of the same super-
natant on 293 cells. Taken together, these data suggest that
NFκB inhibition in HF cells causes defects in HHV8 binding
to target cells and/or viral entry, rather than defects in virion
assembly.
IDENTIFICATION OF HHV8 GENES AFFECTED BY NFκB INHIBITORS
In order to further examine possible HHV8 genes that may be
involved in defective binding or entry into target cells, we per-
formed HHV8 genome wide RNA screening to identify qualitative
differences in gene expression. We found a marked decrease
in expression of several HHV8 lytic genes (data not shown).
Notably, RNA levels of gM, ORF42, and ORF43 were substan-
tially decreased in treated cells. We performed semi-quantitative
real time PCR on RNA harvested from the Induced (no inhibitor)
and Induced + Bay11-7082 treatment groups to confirm these
qualitative results. Expression of all HHV8 RNA was not sta-
tistically significant between treatment and control groups for
the majority of genes screened. However, when NFκB activity
was inhibited, we observed transcriptional down regulation of
ORF16, 29b, 39, 40, 42, and 43 (Figure 5). There was no statisti-
cally significant difference in T1.1 expression affected by NFκB
inhibition, confirming previous results showing no difference
in RFP expression in control versus Bay11-7082 groups when
infected cells were induced to undergo productive replication
(Figures 2B,C). The lower panel of Figure 5 shows, for each
gene, the encoded protein, genome position, orientation and
classification. Because of its role in binding and entry, the gM
protein was of particular interest given that we had found that
viral particles produced in the presence of NFκB appeared to
be inhibited at the binding and entry step. Additionally, despite
the down regulation of viral helicase/primase there was no mea-
surable difference of viral progeny production, which suggests
that expression of these proteins may not be rate limiting in viral
replication.
RESTORATION OF INFECTIVITY BY COMPLEMENTATION WITH gM
Of the identified down regulated viral genes, we tested whether
complementation with gM, a viral envelope protein involved in
viral binding and entry (Koyano et al., 2003; May et al., 2005),
could, at least in part, restore viral infectivity. An expression vec-
tor with an internal ribosome entry site, independent of NFκB,
and including the gM open reading frame was transfected into
rKSHV.219-infected HF cells. Cells were subsequently either mock
treated, electroporated with IκBα-DN, or treated with Bay11-
7082 24 h prior to or after induction. Following induction of
viral replication we quantitated the relative amount of infec-
tious virions produced by measuring GFP forming units on
293 cells. Introduction of gM into infected HF cells induced
to undergo viral reactivation partially restored viral infectivity
that is reduced by NFκB inhibitors (Figure 6). Thus, the block
to viral binding and/or entry when NFκB is inhibited may be
explained in part by insufficient levels of gM in progeny virus
particles.
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FIGURE 5 | Down regulation of HHV8 transcripts. Real time RT-PCR
analysis of RNA harvested from induced rKSHV.219 infected HF cells. Cells
were either treated with DMSO alone (No Inhibitor) or Bay11-7082 and
induced to undergo lytic replication. RNA was extracted and gene expression
quantitated by real time RT-PCR. All values represent fold down regulation
relative to No Inhibitor rKSHV.219 infected HF cells, which was set to 1. RNA
levels were normalized using ribosomal RNA. Information below table
identifies open reading frame, protein name, position in HHV8 genome, NFκB
consensus site upstream of gene, orientation of gene, and immediate early
(IE), early (E), or late (L) gene classification.
DISCUSSION
These data indicate that the HHV8 lytic program in primary
human foreskin fibroblasts and primary microvascular endothe-
lial cells requires NFκB, a cellular transcription factor, to produce
infection competent virions. Inhibition of NFκBduring lytic repli-
cation of HHV8 in primary HF or MVEC leads to a dramatic
decrease in infectious virions. Paradoxically, the decline in viral
titer did not correlate with a decrease in viral particles released,
as similar numbers of viral particles were enumerated between
treatment groups. Virions produced in the presence of NFκB
inhibitors showed a defect in binding and/or entry. This lack of
infectivity correlated with reduced expression of the viral envelope
protein gM (ORF39), as well as tegument (ORF42) and capsid
(ORF43) proteins. These genes, which are in the negative ori-
entation, have NFκB consensus sites upstream within ORF 44.
Interestingly,weobserved adecrease inRNAexpressionof vBCL-2,
a proto-oncogene expressed by numerous gammaherpesvirus dur-
ing latency in B cells (Sarid et al., 1997). This protein is important
in the anti-apoptotic pathway of HHV8-related lymphoma, such
as PEL, demonstrating cell-specific differences in NFκB activity
effects on HHV8 gene expression.
Our data supports amodel inwhich cells undergoing lytic repli-
cation require up-regulation of NFκB for effective expression of
multiple viral proteins including gM, which is involved in virion
production. Neither the inhibitor nor the DN completely shut
down production of NFκB enhanced genes but they did lead to
down-regulation at the transcriptional level, suggesting that these
genes aremost likely expresseddespite the lack of NFκB.Theremay
be a minimum protein concentration required for gM in order to
generate infectious virions, which cannot be reached without full
activation of NFκB. The down regulation of gM results in normal
virion production but inefficient binding and/or entry into target
cells. Our findings are consistent with those found by Grossmann
and Ganem (2008) and Sadagopan et al. (2007) in which NFκB
activity did rise with viral infection but was not involved in infec-
tion, establishment of latency, or viral reactivation. However, our
findings demonstrate that down regulation of NFκB does result in
defective viral particles.
Our results show that NFκB is required for production of infec-
tious virions; however, NFκB levels did not influence entry into
lytic replication. In a previous report, NFκB inhibitors initiated
viral reactivation in PEL cells, although virion production and
infectivity were not addressed (Sgarbanti et al., 2004). In our
current study in HF cells, we observed no viral reactivation in
the presence of NFκB inhibitors without the viral transactivator
ORF50. Differences in these observations may be a result of the
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FIGURE 6 | gM complementation partially reverses loss of infectivity
that results from NFκB inhibition. rKSHV.219 infected HF cells were
transfected with either vector alone () or pIRES-2-gM () and either mock
induced or induced to undergo lytic replication. They were then either mock
treated (No inhibitor), transfected with IκBα-DN or treated with Bay11-7082
prior to induction (Total) or at time of induction (Post). Supernatants were
harvested and GFP forming units on 293 were measured. Samples were
run in triplicate and are representative of three separate experiments. Error
bars represent standard deviations of the mean. *p < 0.0029;
**p < 0.0092; ***p < 0.0202. 1 × 105 cells were used per group in this
assay.
cell types used, as PEL cells are transformed cells that require
NFκB for survival, whereas the primary cells we used do not, thus
demonstrating a clear difference in cell biology ultimately influ-
encing viral reactivation. These findings are in agreement with
studies published by Grossmann and Ganem (2008) suggesting a
true difference in cell biology between transformed and primary
cells exists, as demonstrated by HF cells. However, human umbil-
ical vein endothelial (HuVEC) cells do demonstrate an increase
in lytic replication with inhibition of NFκB. As suggested by the
authors this may be a reflection of cellular context as HuVECs
support lytic replication at baseline without introduction of the
viral transactivator, in contrast to HF cells which produce very low
to undetectable levels of lytic reactivation (Lagunoff et al., 2002;
Vieira and O’Hearn, 2004).
We have also shown that HHV8 viral particles produced in
the presence of NFκB inhibitors are impaired in their ability to
bind and/or enter target cells. The defect in binding and entry was
partially corrected by the introduction of gM in trans to induced
cells suggesting that this protein is amajorplayer in viral infectivity.
A previous report suggests that HHV8 particles produced in the
absence of NFκBare able to enter target cells but unable to establish
de novo infection (Keller et al., 2006). However, in that study the
authors used an extremely high MOI on the order of 5,400, which
makes comparisons difficult.
Viruses often utilize theNFκBpathway for viral gene expression
and/or to promote survival of infected cells. EBV latent membrane
protein-1 (LMP-1) induces abnormal NFκB activation and is asso-
ciated with viral transformation of infected B cells (Luftig et al.,
2004; Stewart et al., 2004). Herpes simplex virus (HSV) requires
increased levels of NFκB activity in order to replicate and release
virions. Blockade of NFκB activity during HSV replication leads to
cellular apoptosis before virions can mature and exit the infected
cell (Gregory et al., 2004). CMV immediate early gene expression
can be initiated by NFκB leading to viral reactivation. In fact,
signaling by TNF in patients following organ and bone marrow
transplantation leads to potent activation of NFκB,which initiates
immediate early gene expression and CMV reactivation resulting
in profound morbidity and mortality (Hummel et al., 2001; Hum-
mel and Abecassis, 2002). Our data add to this body of literature
in which NFκB is utilized by the virus for its lifecycle.
Our findings suggest that using different strategies of NFκB
inhibition may be a valid therapeutic strategy in patients with
uncontrolled viremia, such as in patients receiving immunosup-
pressive therapy; AIDS patients; and at risk patients who have
an increased likelihood of developing HHV8 associated diseases
including PEL andMulticentric Castleman’s disease, both of which
have high levels of lytic viral replication. Additionally, inhibitors
of NFκB such as Bortezomib, a proteasome inhibitor associated
with increased IκBα and β levels in treated cells, may be useful
in decreasing the consequences of HHV8 replication (Matta and
Chaudhary, 2005).
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